SLDB is trading at $9.43 (up 6.4%) as investors focus on the company's Duchenne muscular dystrophy gene therapy pipeline and positive analyst outlooks.
- The stock is extending a strong upward trend that began in mid-June, showing resilience and continued buying interest despite broader market weakness.
- Analysts currently maintain a Strong Buy rating on the stock, pointing toward significant upside price targets based on clinical potential.
- Market sentiment remains buoyed by the progress of Solid Biosciences’ core gene therapy candidates and favorable long-term projections.